产品描述 概述Recombinant Human Interleukin-10 is produced by our Mammalian expression system and the target gene encoding Ser19-Asn178 is expressed. 使用说明This material is offered by Novin Biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. 技术规格| Tag | None | | 种属 | Human | | 表达系统 | Human cells | | Accession# | P22301 | | Source | Human Cells | | Formulation_Description | Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. | | Storage | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7°C for 2-7 days.Aliquots of reconstituted samples are stable at < -20°C for 3 months. | | Reconstitution | Dissolve the lyophilized protein in distilled water. | | Purity | Greater than 95% as determined by reducing SDS-PAGE. | | Endotoxin | Less than 0.1 ng/μg (1 EU/μg) as determined by LAL test. | | Background | Interleukin 10(IL10), also known as cytokine synthesis inhibitory factor (CSIF),is a secreted protein and belongs to the IL-10 family. IL-10 is secreted by many activated hematopoietic cell types as well as hepatic stellate cells, keratinocytes, and placental cytotrophoblasts . IL-10 is an anti-inflammatory TH2 cytokine that has a critical role in limiting the immune response to pathogens to prevent host damage. As IL-10 in produced in several T helper populations, it is proposed that it provides a feedback loop to limit the effector functions of macrophages and DCs on T cells. Once expressed, IL-10 signals through the IL-10 receptor (IL-10R) to activate STAT3. As IL-10 is a strong inhibitor of inflammation, it has become a viable biomarker for various diseases and conditions as well as a therapeutic molecule for certain conditions. In addition to elevated levels in parasitic infection, high expression levels of IL-10 are also found in retroviral infections inducing immunodeficiency. The immunosuppressive properties of IL-10 suggest a possible clinical use of IL-10 in suppressing rejections of grafts after organ transplantations |
|
